Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 11
2003 5
2004 12
2005 7
2006 8
2007 4
2008 9
2009 3
2010 8
2011 8
2012 11
2013 11
2014 2
2015 5
2016 6
2017 4
2018 7
2019 6
2020 4
2021 10
2022 6
2023 6
2024 1
2025 3
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

142 results

Results by year

Filters applied: . Clear all
Page 1
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ; CLARITY Study Group. Giovannoni G, et al. Among authors: rieckmann p. N Engl J Med. 2010 Feb 4;362(5):416-26. doi: 10.1056/NEJMoa0902533. Epub 2010 Jan 20. N Engl J Med. 2010. PMID: 20089960 Free article. Clinical Trial.
Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan K, Rieckmann P, Comi G, Dangond F, Adeniji AK, Vermersch P. Giovannoni G, et al. Among authors: rieckmann p. Mult Scler. 2018 Oct;24(12):1594-1604. doi: 10.1177/1352458517727603. Epub 2017 Sep 5. Mult Scler. 2018. PMID: 28870107 Free article. Clinical Trial.
Serum Alpha-Linolenic Acid and Long-Term Multiple Sclerosis Activity and Progression.
Cortese M, Peng X, Edan G, Freedman MS, Hartung HP, Montalban X, Sandbrink R, Radü EW, Barkhof F, Wicklein EM, Kappos L, Ascherio A, Bjornevik K; BENEFIT Study Group. Cortese M, et al. Neurology. 2025 Aug 12;105(3):e213905. doi: 10.1212/WNL.0000000000213905. Epub 2025 Jul 17. Neurology. 2025. PMID: 40674673 Clinical Trial.
Interferon-beta1b in multiple sclerosis.
Buttmann M, Rieckmann P. Buttmann M, et al. Among authors: rieckmann p. Expert Rev Neurother. 2007 Mar;7(3):227-39. doi: 10.1586/14737175.7.3.227. Expert Rev Neurother. 2007. PMID: 17341170 Review.
Treating multiple sclerosis with monoclonal antibodies.
Buttmann M, Rieckmann P. Buttmann M, et al. Among authors: rieckmann p. Expert Rev Neurother. 2008 Mar;8(3):433-55. doi: 10.1586/14737175.8.3.433. Expert Rev Neurother. 2008. PMID: 18345973 Review.
Functional clinical outcomes in multiple sclerosis: Current status and future prospects.
Karabudak R, Dahdaleh M, Aljumah M, Alroughani R, Alsharoqi IA, AlTahan AM, Bohlega SA, Daif A, Deleu D, Amous A, Inshasi JS, Rieckmann P, Sahraian MA, Yamout BI. Karabudak R, et al. Among authors: rieckmann p. Mult Scler Relat Disord. 2015 May;4(3):192-201. doi: 10.1016/j.msard.2015.03.004. Epub 2015 Mar 23. Mult Scler Relat Disord. 2015. PMID: 26008936 Review.
Improving MS patient care.
Rieckmann P. Rieckmann P. J Neurol. 2004 Sep;251 Suppl 5:v69-v73. doi: 10.1007/s00415-004-1511-z. J Neurol. 2004. PMID: 15549359 Review.
Building up the blood-brain barrier.
Rieckmann P, Engelhardt B. Rieckmann P, et al. Nat Med. 2003 Jul;9(7):828-9. doi: 10.1038/nm0703-828. Nat Med. 2003. PMID: 12835697 No abstract available.
Refining genetic associations in multiple sclerosis.
International Multiple Sclerosis Genetics Consortium (IMSGC). International Multiple Sclerosis Genetics Consortium (IMSGC). Lancet Neurol. 2008 Jul;7(7):567-9. doi: 10.1016/S1474-4422(08)70122-4. Lancet Neurol. 2008. PMID: 18565446 Free PMC article. No abstract available.
142 results